Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited

TLX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.84B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Telix Pharmaceuticals LimitedTelix Pharmaceuticals Limited96.2-13%1.21.2

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.84 Billion
Enterprise Value$3.17 Billion
Earnings per Share$-0.02
Beta0.56
Outstanding Shares339,220,212

Return

Return on Equity13.12%ROE
Return on Assets4.70%
Return on Invested Capital6.03%

Valuation & Multiples

P/E Ratio96.23P/E Ratio
PEG-5.77PEG
Price to Sales1.2Price to Sales
Price to Book Ratio8.37Price to Book Ratio
Enterprise Value to Revenue1.27
Enterprise Value to EBIT46.96
Enterprise Value to Net Income49
Total Debt to Enterprise0.18
Debt to Equity1.19Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 19, 2026
EPS
$0.11
Est. $0.04
Revenue
$477.00 M
Est. $479.63 M

Next Earnings Call

Expected Date
February 19, 2027
EPS Estimate
-$0.04
Consensus analyst estimate
Revenue Estimate
$493.84 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.59%▼ 0.35%
Total Invested$22.08M▼ 39.71%
Investors Holding40▼ 22.00%

About Telix Pharmaceuticals Limited

1,184 employees
CEO: Christian Behrenbruch

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medi...

Telix Pharmaceuticals Limited Insider Information FAQ

Stockcircle shows 1 open-market insider purchase for Telix Pharmaceuticals Limited in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.

Questions & Answers